+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sarepta Therapeutics - logo

Sarepta Therapeutics is a biopharmaceutical company that focuses on the development of RNA-based therapeutics for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD). It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

From
From
Oligonucleotide Therapy Market Report 2026 - Product Thumbnail Image

Oligonucleotide Therapy Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
From
Duchenne Muscular Dystrophy - Global Clinical Trials Review, 2025 - Product Thumbnail Image

Duchenne Muscular Dystrophy - Global Clinical Trials Review, 2025

  • Clinical Trials
  • April 2025
  • 302 Pages
  • Global
From
Vaccine Contract Manufacturing Market Report 2026-2036 - Product Thumbnail Image

Vaccine Contract Manufacturing Market Report 2026-2036

  • Report
  • January 2026
  • 314 Pages
  • Global
From
From
From
From
Collaboration Deals in Pharmaceuticals 2020-2026 - Product Thumbnail Image

Collaboration Deals in Pharmaceuticals 2020-2026

  • Report
  • March 2026
  • 850 Pages
  • Global
From
Mitoxantrone Hydrochloride Market - Global Forecast 2026-2032 - Product Thumbnail Image

Mitoxantrone Hydrochloride Market - Global Forecast 2026-2032

  • Report
  • September 2026
  • 180 Pages
  • Global
From
From
From
Loading Indicator